메뉴 건너뛰기




Volumn 4, Issue 1 SUPPL. 1, 2008, Pages

We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development

Author keywords

Alzheimer's disease; Clinical trials; Disease modifying treatment; Symptomatic treatment

Indexed keywords

ACTIVTE MONOCLONAL VACCINE; ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID ANTIBODY; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; GLIAL CELL MODULATOR; HOMOTAURINE; MEMANTINE; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; NEUROTROPIC AGENT; NOOTROPIC AGENT; NUTRACEUTICAL; PLACEBO; PROTEIN ANTIBODY; PSYCHOTROPIC AGENT; SECRETASE INHIBITOR; TACRINE; TARENFLURBIL; TAU ANTIBODY; UNCLASSIFIED DRUG;

EID: 38049027779     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.010     Document Type: Editorial
Times cited : (18)

References (21)
  • 1
    • 0022899577 scopus 로고
    • Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
    • Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., and Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315 (1986) 1241-1245
    • (1986) N Engl J Med , vol.315 , pp. 1241-1245
    • Summers, W.K.1    Majovski, L.V.2    Marsh, G.M.3    Tachiki, K.4    Kling, A.5
  • 2
    • 0032507788 scopus 로고    scopus 로고
    • Donepezil improves cognition and global funtion in Alzheimer disease
    • Donepexil Study Group
    • Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T., and Donepexil Study Group. Donepezil improves cognition and global funtion in Alzheimer disease. Arch Intern Med 158 (1998) 1021-1031
    • (1998) Arch Intern Med , vol.158 , pp. 1021-1031
    • Rogers, S.L.1    Doody, R.S.2    Mohs, R.C.3    Friedhoff, L.T.4
  • 3
    • 0031883716 scopus 로고    scopus 로고
    • A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
    • Donepezil Study Group
    • Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T., and Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
    • (1998) Neurology , vol.50 , pp. 136-145
    • Rogers, S.L.1    Farlow, M.R.2    Doody, R.S.3    Mohs, R.4    Friedhoff, L.T.5
  • 4
    • 0029790469 scopus 로고    scopus 로고
    • Observations and suggestions on antidementia drug development
    • Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 Suppl1 (1996) 31-35
    • (1996) Alzheimer Dis Assoc Disord , vol.10 , Issue.Suppl1 , pp. 31-35
    • Leber, P.1
  • 5
    • 0033679259 scopus 로고    scopus 로고
    • A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
    • Farlow M., Anand R., Messina Jr. J., Hartman R., and Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44 (2000) 236-241
    • (2000) Eur Neurol , vol.44 , pp. 236-241
    • Farlow, M.1    Anand, R.2    Messina Jr., J.3    Hartman, R.4    Veach, J.5
  • 6
    • 0035103036 scopus 로고    scopus 로고
    • Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    • Donepezil Study Group
    • Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., Pratt R.D., and Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
    • (2001) Arch Neurol , vol.58 , pp. 427-433
    • Doody, R.S.1    Geldmacher, D.S.2    Gordon, B.3    Perdomo, C.A.4    Pratt, R.D.5
  • 7
    • 1042291157 scopus 로고    scopus 로고
    • The cognitive benefits of galantamine are sustained for at least 36 months
    • Raskind M.A., Peskind E.R., Truyen L., Kershaw P., and Damaraju C.R.V. The cognitive benefits of galantamine are sustained for at least 36 months. Arch Neurol 61 (2004) 252-256
    • (2004) Arch Neurol , vol.61 , pp. 252-256
    • Raskind, M.A.1    Peskind, E.R.2    Truyen, L.3    Kershaw, P.4    Damaraju, C.R.V.5
  • 9
    • 33645756861 scopus 로고    scopus 로고
    • Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?
    • Sabbagh M.N., Farlow M.R., Relkin N., and Beach T.G. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. Alzheimer's & Dementia 2 (2006) 118-125
    • (2006) Alzheimer's & Dementia , vol.2 , pp. 118-125
    • Sabbagh, M.N.1    Farlow, M.R.2    Relkin, N.3    Beach, T.G.4
  • 10
    • 34748915821 scopus 로고    scopus 로고
    • Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease
    • Gunnarsson M.D., Kilander L., Basun H., and Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2007) 247-252
    • (2007) Dement Geriatr Cogn Disord , vol.24 , pp. 247-252
    • Gunnarsson, M.D.1    Kilander, L.2    Basun, H.3    Lannfelt, L.4
  • 11
    • 0030865454 scopus 로고    scopus 로고
    • Slowing the progression of Alzheimer disease: methodologic issues
    • Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11 (1997) S10-S21
    • (1997) Alzheimer Dis Assoc Disord , vol.11
    • Leber, P.1
  • 13
    • 0034099077 scopus 로고    scopus 로고
    • Using serial-registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects
    • Fox N.C., Cousens S., Scahill R., Harvey R.J., and Rosser M.N. Using serial-registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57 (2000) 339-344
    • (2000) Arch Neurol , vol.57 , pp. 339-344
    • Fox, N.C.1    Cousens, S.2    Scahill, R.3    Harvey, R.J.4    Rosser, M.N.5
  • 14
    • 23944435182 scopus 로고    scopus 로고
    • Changing patient characteristics and survival experience in an Alzheimer's center patient cohort
    • Doody R., Pavlik V., Massman P., Kenan M., Yeh S., Powell S., et al. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord 20 (2005) 198-208
    • (2005) Dement Geriatr Cogn Disord , vol.20 , pp. 198-208
    • Doody, R.1    Pavlik, V.2    Massman, P.3    Kenan, M.4    Yeh, S.5    Powell, S.6
  • 15
    • 0035099794 scopus 로고    scopus 로고
    • A method for estimating progression rates in Alzheimer disease
    • Doody R.S., Massman P., and Dunn J.K. A method for estimating progression rates in Alzheimer disease. Arch Neurol 58 (2001) 449-454
    • (2001) Arch Neurol , vol.58 , pp. 449-454
    • Doody, R.S.1    Massman, P.2    Dunn, J.K.3
  • 16
    • 0035001864 scopus 로고    scopus 로고
    • Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
    • Doody R.S., Dunn J.K., Clark C.M., Farlow M., Foster N.L., Liao T., et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12 (2001) 295-300
    • (2001) Dement Geriatr Cogn Disord , vol.12 , pp. 295-300
    • Doody, R.S.1    Dunn, J.K.2    Clark, C.M.3    Farlow, M.4    Foster, N.L.5    Liao, T.6
  • 18
    • 38049039184 scopus 로고    scopus 로고
    • Exposure to antidementia drugs slows clinical progression of Alzheimer's disease (AD)
    • Rountree S., Chan W., Doody R., Pavlik V., Darby E., Saddiqui S., et al. Exposure to antidementia drugs slows clinical progression of Alzheimer's disease (AD). Ann Neurol 62 Suppl 11 (2007) S55
    • (2007) Ann Neurol , vol.62 , Issue.SUPPL. 11
    • Rountree, S.1    Chan, W.2    Doody, R.3    Pavlik, V.4    Darby, E.5    Saddiqui, S.6
  • 19
    • 35848962080 scopus 로고    scopus 로고
    • Disease-modifying therapies for Alzheimer disease. challenges to early intervention
    • Cummings J., Doody R., and Clark C. Disease-modifying therapies for Alzheimer disease. challenges to early intervention. Neurology 69 (2007) 1622-1634
    • (2007) Neurology , vol.69 , pp. 1622-1634
    • Cummings, J.1    Doody, R.2    Clark, C.3
  • 20
    • 38049012255 scopus 로고    scopus 로고
    • Model-based longitudinal data analysis can lead to more efficient drug development. a case study
    • EPub April 27
    • Jadhav P.R., and Gobburu J.V.S. Model-based longitudinal data analysis can lead to more efficient drug development. a case study. FDA Science Forum (2005) EPub April 27
    • (2005) FDA Science Forum
    • Jadhav, P.R.1    Gobburu, J.V.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.